The evolution of assays for immuno-oncology research
Drug Discovery World
FEBRUARY 15, 2023
Genetically modified T cells stimulated with IL2 are now administered as cell therapy for multiple cancer cell types with beneficial results 3,4. To date, several preclinical IO models have been developed, with each type having their respective strengths and weaknesses. This continues to be the standard of care.
52 
Let's personalize your content